Tuesday 17 November 2026 Sign in / SubscribeFree daily emailMarket analysisEnterpriseVigiEye regulatory newsCompePharma CRM & HR →
The business of pharma
Pipeline & R&D

Galectin sends belapectin pivotal trial plan to FDA; chairman swaps $105.8M debt for equity

The small-cap liver drug developer has $11.7M in cash, guided to last until June 2027, and has not said how it will pay for a registrational cirrhosis study.

16 Nov 2026 · Galectin Therapeutics Inc GALT · Company news

Galectin Therapeutics has taken a step towards a pivotal trial of belapectin, submitting the study protocol to the US Food and Drug Administration. The drug is aimed at patients with MASH cirrhosis and portal hypertension. The company disclosed the filing alongside its results for the quarter ended 30 September 2026, published on 16 November.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on CompePharma and VigiEye
  • One subscription for both sites, cancel any time

Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.

We'll email you a link to confirm your address, then take you to secure checkout (Stripe). Billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. Already a subscriber? Enter your email and the link will sign you in. See our terms and privacy policy.

Company's press release (SEC filing): Galectin Therapeutics Inc ↗

Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.

More Pipeline & R&DAll →